<DOC>
	<DOC>NCT00917748</DOC>
	<brief_summary>The primary objective is: - To determine the efficacy of modafinil in the reduction of fatigue in patients with metastatic breast or prostate cancer undergoing docetaxel-based chemotherapy The secondary objectives are: - To determine the effect of modafinil on quality of life (QoL) during docetaxel-based chemotherapy - To determine the effect of modafinil on patients physical activity level, functional status, number of chemotherapy cycles tolerated, sleep disturbance and depression, during docetaxel-based chemotherapy - To investigate the impact of tumour type, patient physical activity level, functional status, sleep disturbance and depression on the efficacy of modafinil at improving fatigue and quality of life during docetaxel-based chemotherapy. - To determine the safety and tolerability of modafinil during docetaxel-based chemotherapy</brief_summary>
	<brief_title>Study With Modafinil in Patients Treated With Docetaxel-Based Chemotherapy for Metastatic Breast or Prostate Cancer (MOTIF)</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<criteria>Inclusion criteria: Treatment with q3w (every three weeks) docetaxelbased chemotherapy for metastatic breast or prostate cancer at a minimum dose of 50 mg/m2 Completed at least two cycles of chemotherapy and intention to treat the patient with at least two further cycles of docetaxelbased chemotherapy Fatigue &gt; or = to 4 on the MD Anderson Symptom Inventory fatigue assessment scale during the previous docetaxel chemotherapy cycle SPHERE somatic (SOMA) subscale score &gt; or = to 3 Worsening of fatigue after commencement of docetaxel chemotherapy Haemoglobin (Hb)&gt; or = to 10 g/dL within two weeks before randomisation Exclusion criteria: Unable to complete the MD Anderson Symptom Inventory fatigue assessment scale or Functional Assessment of Chronic Illness TherapyFatigue Quality of Life survey Require docetaxel chemotherapy dose reduction to less than 50 mg/m2 History of chronic fatigue condition Uncontrolled hypertension (blood pressure &gt; or = to 150/90 mm Hg Known hypersensitivity / intolerance to modafinil or any of the excipients Pregnant women Psychological, familial, sociological, or geographical conditions that do not permit treatment or medical followup and / or prohibit compliance with the study protocol Any serious concomitant illness that, in the opinion of the Investigator, would preclude a patient from participating in the study NonEnglish speaking The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>